| Trial ID: | L0718 |
| Source ID: | NCT00172809
|
| Associated Drug: |
Peginterferon Alfa-2a
|
| Title: |
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Hepatitis C|End Stage Renal Disease
|
| Interventions: |
DRUG: Peginterferon alfa-2a|DRUG: Interferon alfa-2a
|
| Outcome Measures: |
Primary: Sustained histological response and sustained virological response 6 months after the completion of the intervention, 1 year | Secondary: The overall tolerance of the two different regimens and the comparison of the rates of side effects, 1 year
|
| Sponsor/Collaborators: |
Sponsor: National Taiwan University Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-07
|
| Completion Date: |
2007-01
|
| Results First Posted: |
|
| Last Update Posted: |
2008-03-06
|
| Locations: |
National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan
|
| URL: |
https://clinicaltrials.gov/show/NCT00172809
|
